Abstract
AFTER MONTHS of talk about shortcomings in the way the Food and Drug Administration (FDA) goes about its job, Congress is finally moving toward developing comprehensive legislation that will, it is hoped, improve the agency's performance. Sen Nancy Kassebaum (R, Kan), chair of the Labor and Human Resources Committee, is holding congressional hearings on legislation she introduced in December. On the House side, Thomas J. Bliley, Jr (R, Va), chair of the Commerce Committee, has promised that he too will hold hearings on legislation that he proposes to introduce. Bliley has been a severe critic of the agency. Although not all will agree that Kassebaum's bill is the perfect solution to resolving the problems that many say plague the FDA and regardless of the outcome, her bill has substantially moved the debate about the agency's performance from charges and countercharges to a serious effort at reform. The US Congress has
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
